Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies

George Robinson, … , Coziana Ciurtin, Elizabeth C. Jury


Suppressing inflammation has been the primary focus of therapies in autoimmune rheumatic diseases (AIRDs), including rheumatoid arthritis and systemic lupus erythematosus. However, conventional therapies with low target specificity can have effects on cell metabolism that are less predictable. A key example is lipid metabolism; current therapies can improve or exacerbate dyslipidemia. Many conventional drugs also require in vivo metabolism for their conversion into therapeutically beneficial products; however, drug metabolism often involves the additional formation of toxic by-products, and rates of drug metabolism can be heterogeneous between patients. New therapeutic technologies and research have highlighted alternative metabolic pathways that can be more specifically targeted to reduce inflammation but also to prevent undesirable off-target metabolic consequences of conventional antiinflammatory therapies. This Review highlights the role of lipid metabolism in inflammation and in the mechanisms of action of AIRD therapeutics. Opportunities for cotherapies targeting lipid metabolism that could reduce immunometabolic complications and potential increased cardiovascular disease risk in patients with AIRDs are discussed.

Find the latest version:

https://jci.me/148552/pdf
Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies

George Robinson,1,2 Ines Pineda-Torra,3 Coziana Ciurtin,1,2 and Elizabeth C. Jury1

1Centre for Rheumatology Research, 2Centre for Adolescent Rheumatology Research, and 3Centre for Cardiometabolic and Vascular Science, Division of Medicine, University College London, London, United Kingdom.

Suppressing inflammation has been the primary focus of therapies in autoimmune rheumatic diseases (AIRDs), including rheumatoid arthritis and systemic lupus erythematosus. However, conventional therapies with low target specificity can have effects on cell metabolism that are less predictable. A key example is lipid metabolism; current therapies can improve or exacerbate dyslipidemia. Many conventional drugs also require in vivo metabolism for their conversion into therapeutically beneficial products; however, drug metabolism often involves the additional formation of toxic by-products, and rates of drug metabolism can be heterogeneous between patients. New therapeutic technologies and research have highlighted alternative metabolic pathways that can be more specifically targeted to reduce inflammation but also to prevent undesirable off-target metabolic consequences of conventional antiinflammatory therapies. This Review highlights the role of lipid metabolism in inflammation and in the mechanisms of action of AIRD therapeutics. Opportunities for cotherapies targeting lipid metabolism that could reduce immunometabolic complications and potential increased cardiovascular disease risk in patients with AIRDs are discussed.

Introduction

The inflammation associated with autoimmune rheumatic diseases (AIRDs), including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), is dependent on multiple immune cell subsets within disease-specific settings, each having different metabolic demands (1). For example, effector T cells are dependent on glycolytic metabolism for their growth and effector functions, whereas regulatory T cells utilize lipids via mitochondrial β-oxidation and the generation of ATP through oxidative phosphorylation (OXPHOS) (2). Naïve B cells are maintained in a reduced metabolic state, while their activation relies on metabolic programming toward OXPHOS (3). Similarly, during inflammation, inflammatory M1 macrophages use glycolysis, whereas more anti-inflammatory M2 macrophages typically use β-oxidation (4). Autoimmune responses in AIRDs have high energy demands and involve elevated lipogenesis, glucose and glutamine metabolism, and a switch toward cellular glycolysis from OXPHOS for energy metabolism. For example, hypoxia in the RA synovium induces chronic T cell mitochondrial hyperpolarization associated with increased glucose metabolism and ATP synthesis, and in SLE patients and lupus-prone mice, chronically activated T cells have increased mitochondrial glucose oxidation and hyperpolarization, as reviewed previously (1, 5). Many of the current therapies for AIRDs influence lipid metabolic pathways to exert their therapeutic benefit; furthermore, lipid metabolism could play a role in the pathogenesis of AIRDs and associated comorbidities. This Review discusses lipid metabolism in inflammation and mechanisms of action of AIRD therapeutics, addresses the on- and off-target metabolic effects induced by these therapies, and highlights opportunities for cotherapies targeting lipid metabolism that could benefit patients, with a focus on cardiovascular disease (CVD) risk, an important comorbidity in patients with AIRDs.

Lipid metabolic pathways in inflammation

Lipid metabolism is a crucial aspect of cellular metabolism and effective immune responses; lipids derived from both de novo biosynthesis and exogenous sources are essential for fuel and growth and as membrane components, and mediate cell signaling (6), as summarized in Figure 1. Aspects of lipid metabolism that could contribute to disease pathogenesis and associated comorbidities in patients with AIRDs and serve as therapeutic targets are outlined below.

Immune cell lipid membranes and dyslipidemia

Immune cell plasma membranes comprise a phospholipid bilayer containing highly ordered areas enriched in glycosphingolipids and cholesterol, called lipid rafts. Immune cell surface receptors (including T cell and B cell receptors and costimulatory molecules) reside within lipid rafts and facilitate appropriate cell signaling in response to antigen or other cellular ligands (refs. 7–9 and Figure 1, A–C). Lipid rafts are altered in SLE, in which an increase in both cell membrane glycosphingolipids and cholesterol attributable to increased cellular lipid synthesis is associated with increased T cell and B cell receptor signaling and ultimately activation and inflammation (10, 11). Circulating lipids also play a role in immune cell function, through lipid uptake from VLDL or LDL via the VLDL or LDL receptor (VLDLR or LDLR), respectively, or from HDL via scavenger receptor class B type 1 (SR-BI) and CD36; or through lipid efflux to HDL or apolipoprotein A1 via ATP-binding cassette transporter A1 (ABCA1) and ABCG1. Both uptake and efflux influence cellular lipid burden and function (ref. 12 and Figure 1C). This is of particular importance...
patients with active RA (19), highlighting the prevalence of this form of HDL in AIRDs that is rarely measured and could be associated with elevated cardiovascular risk.

Pro- and antiinflammatory lipid metabolism

Proinflammatory lipids including eicosanoids contribute to some of the typical clinical symptoms associated with many AIRDs, such as joint pain, stiffness, and swelling (ref. 20 and Figure 1D). Eicosanoids are produced following the phospholipase A2–mediated release of arachidonic acid from membrane phospholipids (21). Arachidonic acid (AA) is a major substrate for proinflammatory prostaglandins (PGs), which contribute to many AIRD symptoms, including joint pain and swelling. AA is also involved in the production of proinflammatory eicosanoids, which can exacerbate the inflammation in AIRDs.

In AIRDs, there are alterations in lipoprotein metabolism. Reduced serum total cholesterol, triglycerides, and LDL-cholesterol (LDL-C) in patients with untreated RA that increase when patients are treated (the so-called lipid paradox in RA; ref. 14), and elevated LDL-C and medium-chain/free fatty acids and reduced HDL and long-chain fatty acids in SLE (15–18). Interestingly, a dysfunctional proinflammatory HDL, lacking the antioxidant capacity of conventionally cardioprotective HDL, is described in 48.2% of women with SLE (15), and in patients with active RA (19), highlighting the prevalence of this form of HDL in AIRDs that is rarely measured and could be associated with elevated cardiovascular risk.

Pro- and antiinflammatory lipid metabolism

Proinflammatory lipids including eicosanoids contribute to some of the typical clinical symptoms associated with many AIRDs, such as joint pain, stiffness, and swelling (ref. 20 and Figure 1D). Eicosanoids are produced following the phospholipase A2–mediated release of arachidonic acid from membrane phospholipids (21). Arachidonic acid (AA) is a major substrate for proinflammatory prostaglandins (PGs), which contribute to many AIRD symptoms, including joint pain and swelling. AA is also involved in the production of proinflammatory eicosanoids, which can exacerbate the inflammation in AIRDs.
acid (an essential polyunsaturated omega-6 fatty acid) is subsequently converted into active metabolites by cyclooxygenase (COX), lipoxigenase, and cytochrome p450 (CYP) enzymes (20, 22). Downstream eicosanoid signaling can have a direct metabolic effect on immune cell subsets via the modulation of PPARs, nuclear hormone receptors that mediate antiinflammatory effects and modulate liver X receptors (LXRs), regulators of cholesterol homeostasis (23). Prostaglandin signaling can either stimulate (prostaglandin D$_2$) or inhibit (prostaglandins F$_{2\alpha}$ and E$_{2\alpha}$) the antiinflammatory ability of PPAR$\gamma$ to antagonize NF-$\kappa$B in multiple immune cells, including T cells, B cells, macrophages, and dendritic cells (refs. 24, 25, and Figure 1E). PPAR$\gamma$ has been detected in macrophage-rich regions of human atherosclerotic plaques, where it controls lipid homeostasis and inhibits activation induced by proinflammatory cytokines (26). Although the functions of PPARs are tissue specific, some functions affecting lipid-protein metabolism include induction of lipolysis, reduced cellular triglyceride synthesis and VLDL production, enhanced intracellular lipid metabolism could influence long-term outcomes (45).

Ferroptosis is a form of regulated cell death driven by iron-dependent lipid oxidation (Figure 1F). Peroxidation of phospholipids containing polyunsaturated fatty acids is mediated by iron overload (free iron and iron-dependent lipoxigenases) and ROS. Under normal homeostatic conditions, cells can eliminate products of lipid peroxidation via several complex mechanisms (including glutathione peroxidase 4, an inhibitor of phospholipid peroxidation); however, in numerous conditions, including inflammation, these mechanisms are defective, leading to cell membrane damage and ferroptosis (35). Notably, increased ROS levels induced during inflammation in AIRDs could contribute to increased ferroptosis (36). Higher concentrations of free iron and other iron-binding proteins in synovial fluid and infusion of iron-dextran increase lipid peroxidation, decrease red cell glutathione, and exacerbate RA synovitis (36). In SLE, increased dietary iron and iron infusion also exacerbate disease activity (37). However, it remains to be confirmed whether inhibiting ferroptosis could be beneficial in AIRDs (36, 37).

Nonsteroidal antiinflammatory drugs

Eicosanoids are drivers of inflammation in AIRDs and are major targets of antiinflammatory therapies, including nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit prostaglandin synthesis through the inhibition of COX enzymes (ref. 20 and Table 1). NSAIDs include both nonselective NSAIDs (e.g., aspirin, ibuprofen, diclofenac, phenylbutazone, mefenamic acid) and selective COX-2 inhibitors (e.g., celecoxib and rofecoxib) (38). The antiinflammatory potency of COX-2 inhibitors is higher than that of nonselective NSAIDs, which is reflected in better clinical outcomes in RA and other types of inflammatory arthritis (39, 40). While all COX inhibitors are effective at treating inflammation, their side effects include cardiovascular, gastrointestinal, and renal complications (41). Of relevance to AIRDs is the association of selective COX-2 inhibition with increased risk of thrombotic events. Thromboxane A$_2$ is an eicosanoid lipid mediator derived mainly from activated platelets, which constitutively express only COX-1. Thromboxane A$_2$ induces vasocostriction, endothelial adhesion molecule expression, and platelet aggregation and production among other effects, and is elevated in cardiovascular and inflammatory diseases; whereas COX-2 mediates the production of prostacyclin, which mediates vasodilation, inhibits platelet aggregation, and restrains the cardiovascular effects of thromboxane A$_2$. Thus, both thromboxane A$_2$ and prostacyclin are important mediators of CVD risk (42). CVD risk may also be associated with localized alterations in prostaglandin metabolism and PPAR$\gamma$ activity where the COX isofoms are coexpressed in atherosclerotic plaques (43, 44). Consequently, while COX-1 inhibition protects against atherosclerotic progression (for example, low-dose aspirin inhibits platelet-derived thromboxane A$_2$), selective COX-2 inhibitors block cardioprotective prostacyclin and are associated with increased CVD risk (45). In clinical practice, individual CVD risk can be predicted using validated clinical scores; however, the complexity and heterogeneity of therapeutic responses and their direct or indirect impact on lipid metabolism could influence long-term outcomes (45).
important to measure these adverse metabolic effects against clinical benefits (48). Baseline lipid profile is considered when patients are started on corticosteroids, but the clinical need for treatment likely takes priority. If prednisolone treatment is of short duration (e.g., acute flare of gout, bridging therapy in RA) (56), then dyslipidemia is not clinically managed in any particular way. However, long-term prednisolone treatment requires monitoring of lipid profile as indicated in various guidelines and as part of CVD risk management recommendations (53, 57).

Hydroxychloroquine. Despite the widespread use and efficacy of hydroxychloroquine in the treatment of AIRDs (58), its mechanism of action is relatively unclear. It has beneficial effects on lipid and glucose metabolism but also exerts multiple other immunomodulatory actions (ref. 59 and Table 1). The atheroprotective role of hydroxychloroquine is likely due to both its antiinflammatory and its lipid-modifying effects. Hydroxychloroquine is protective against endothelial cell damage, hypertension, and thrombosis (CVD risk factors) via the inhibition of endothelin-1 (a potent vasoconstrictor), downregulation of proinflammatory cytokines such as TNF-α, and reduced levels of proinflammatory ROS, which inhibit platelet...

Figure 2. Summary of the mechanisms of action of current therapies used in AIRDs. Schematic representation summarizing the key mechanistic pathways affected by both traditional and modern therapies used to treat AIRDs, including disease-modifying antiinflammatory drugs (DMARDs), target synthetic DMARDs (tsDMARDs), nonsteroidal antiinflammatory drugs (NSAIDs), steroids, and biologics. The majority of these therapeutics result in the modification of immune functions and metabolic pathways through alterations in gene transcription. These pathways provide insight into opportunities for cotherapies to prevent off-target immunometabolic effects. AA, arachidonic acid; Aza, azathioprine; CP, cyclophosphamide; GF, growth factor; GR, glucocorticoid receptor; HCQ, hydroxychloroquine; NF-κB, nuclear factor NF-κB (p50/p52/RelA/RelB); iκB, inhibitor of κB; MAP2/3K, mitogen-activated protein 2-kinase or 3-kinase; MMF, mycophenolate mofetil; MTX, methotrexate; NFAT, nuclear factor of activated T cells; PG, prostaglandin; R, receptor; RXR, retinoid X receptor; SASP, sulfasalazine; SYK, spleen-associated tyrosine kinase; TCR, T cell receptor.
could interfere with the efficacy of combination therapies that are associated with the metabolism of many drugs; thus, it remains largely unknown. There is evidence that aggregation (60–62).

The mechanisms underlying its direct effect on lipid metabolism remain largely unknown. There is evidence that hydroxychloroquine reduces atherogenic triglycerides and total and LDL-cholesterol and increases atheroprotective HDL-cholesterol (63, 64). Hydroxychloroquine is also a substrate for CYP enzymes, which are associated with the metabolism of many drugs; thus, it could interfere with the efficacy of combination therapies that are metabolized via the CYP pathway, including calcineurin inhibitors (59, 65), or increase the cardiovascular risk in association with various antibiotics (66). Hydroxychloroquine-mediated changes in lipid metabolism could influence immune cell function. Interestingly, research investigating hydroxychloroquine in SARS-CoV-2 infection shows that the drug binds to sialic acid–containing glycolipids within plasma membrane lipid rafts and inhibits viral uptake (67).

### Table 1. Mechanisms of action of current conventional therapies used in AIRDs (part 1)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanisms/effects</th>
<th>Effects on lipid metabolism</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSAIDS</td>
<td>Inhibit CDX-1 and CDX-2 enzymes, which catalyze production of lipid-based metabolic mediators (eicosanoids), e.g., prostaglandins and leukotrienes. Prostaglandins are unsaturated fatty acids that have diverse effects, including vasodilation, pain, platelet aggregation, and stomach acid secretion, and contribute to clinical symptoms such as joint pain, stiffness, and swelling. CDX-1 is ubiquitously expressed and has important homeostatic functions. CDX-2 is upregulated by proinflammatory cytokines via NF-κB signaling at sites of inflammation and is the primary source of prostaglandin production in AIRDs including RA and SLE.</td>
<td>Inhibits the production of lipid-based metabolic mediators (eicosanoids), including prostaglandins and leukotrienes.</td>
<td>20, 45, 190–193</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>Reduces inflammation and is a cornerstone treatment for many AIRDs. Lipophilic and binds to GCRs in the cytoplasm. Ligand-bound GCRs are dissociated from chaperone proteins, where they inhibit NF-κB activation and the transcription of inflammatory genes. Activated GCRs also bind to and inhibit the activity of JNK, and components of the T cell receptor signaling pathway, thereby reducing inflammation. Ligand-bound GCRs translocate to the nucleus, bind to glucocorticoid response elements, induce the transcription of antiinflammatory genes, and inhibit proinflammatory genes by binding to upstream genomic regions. Can induce hyperglycemia and increase the risk of diabetes through the transcriptional induction of phagocytosis via NF-κB and COX-2. Reduces atherogenic triglycerides and total cholesterol and increases HDL-C. Reduces lymphocyte proliferation and inflammatory responses. Inhibits proinflammatory cytokine production.</td>
<td>Effects of long-term use include hypertension, obesity, dyslipidemia, and atherosclerosis. Promotes fatty acid synthase and acetyl-CoA carboxylase activation and inhibition of fatty acid β-oxidation by blocking acyl-CoA dehydrogenase activity. Induces hepatic fat accumulation and increased circulating triglycerides and VLDL.</td>
<td>48–51, 194–196</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>A lipophilic, weak base that accumulates in acidic environments including intracellular vesicles (lysosomes, endosomes, autophagosomes) and inflamed tissue. Alters lysosomal function and autophagy by inhibiting endosomal trafficking, endosome–lysosome fusion, and lysosomal protease activity via changes in endosomal pH. Inhibits antigen presentation by altering degradation of phagocytosed peptides and inhibiting MHC class II antigen presentation. Slows insulin metabolism and reduces hyperglycemia in patients with non–insulin-dependent diabetes. Prevents endosomal TLR signaling, via steric binding to ligands (e.g., TLR7 and TLR9 binding their respective ligands RNA and DNA). Inhibits proinflammatory cytokine production.</td>
<td>Protective against endothelial cell damage, hypertension, and thrombosis via the inhibition of endothelin-1 (a potent vasoconstrictor), downregulation of proinflammatory cytokines such as TNF-α, and reduced levels of proinflammatory ROS, which inhibit platelet aggregation. Reduces atherogenic triglycerides and total cholesterol and LDL-C and increases HDL-C. Is a substrate for CYP enzymes, associated with the metabolism of many drugs. Binds to sialic acid–containing glycolipids within plasma membrane lipid rafts and inhibits viral uptake. Disrupts lysosomal membranes; therefore, it could modify lipid raft–mediated immune cell signaling.</td>
<td>9, 59–64, 67, 68, 197–201</td>
</tr>
<tr>
<td>Calcineurin inhibitors</td>
<td>Inhibit dephosphorylation and nuclear transfer of NFAT, via the cytoplasmic calcium/calmodulin pathway, thereby blocking T cell activation and transcription of proinflammatory mediators and IL-2, and upregulation of glucose transporters and glycolytic enzymes that support nutrient supply for T cell proliferation and inflammatory responses. Block NF-κB and MAPK signaling. Significant off-target effects include high renal toxicity (associated with alterations in electrolyte availability including hyperkalemia, metabolic acidosis, hypercalciuria, and hyperuricemia).</td>
<td>Impair endothelial cell function associated with CDX-2 inhibition and reduced prostaglandin E_2 production. Dyslipidemia (increased total cholesterol, LDL-C, triglycerides, apolipoprotein B). Reduced hepatic LDL clearance and increased cholesterol biosynthesis via the HMG-CoA pathway mediated by inhibition of 37-hydroxycholesterol, an oxysterol that inhibits cholesterol metabolism via HMG-CoA. Inhibit bile acid synthesis via 26-hydroxylation and could reduce triglyceride degradation by inhibiting lipoprotein lipase activity.</td>
<td>69–72, 74, 75, 202–205</td>
</tr>
</tbody>
</table>

Overview of the mechanisms of action of therapies used for patients with AIRDs and their effect on lipid metabolism pathways. GCR, glucocorticoid receptor; HMG-CoA, 3-hydroxy-3-methylglutaryl–coenzyme A; NFAT, nuclear factor of activated T cells; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; TLR, Toll-like receptor.
It has also been shown to disrupt lysosomal membranes; therefore, hydroxychloroquine could also mediate its effects in AIRDs by modifying lipid raft–mediated immune cell signaling, which can in turn modulate immune cell function (refs. 9, 68, and Figure 1A).

Calcineurin inhibitors. Calcineurin inhibitors (cyclosporin, voclosporin, tacrolimus) block T cell signaling and activation (Table 1) but also have noteworthy off-target effects, including impairment of endothelial cell function associated with COX-2 inhibition and reduced production of prostaglandin E, (69) and dyslipidemia (increased total cholesterol, LDL-C, triglycerides, and apolipoprotein B) (70, 71). Various mechanisms could contribute to altered lipid levels, including reduced hepatic LDL-C clearance and increased cholesterol biosynthesis via the HMG-CoA pathway mediated by inhibition of 27-hydroxycholesterol, an oxysterol that inhibits cholesterol metabolism via HMG-CoA (ref. 72 and Figure 1C). Interestingly, voclosporin, recently approved for use in adult lupus nephritis, shows a significant reduction in total cholesterol and LDL-C, potentially due to its superior antiinflammatory properties (73). Cyclosporin also inhibits bile acid synthesis via 26-hydroxylase and could reduce triglyceride degradation by inhibiting lipoprotein lipase activity (71, 74). Thus, although calcineurin inhibitors are favorable in AIRDs, further mechanistic research is required to assess the antiinflammatory benefits against the off-target effects of blocking fundamental metabolic processes.

Mycophenolate mofetil and azathioprine. Mycophenolate mofetil (MMF) and azathioprine inhibit cellular proliferation through inhibition of purine nucleotide synthesis pathways (refs. 75 and Table 2). Mycophenolic acid (the active metabolite of MMF) can also activate PPARγ (76) and increase intracellular lipids including fatty acids, cholesterol, and phosphatidylcholine in vitro (77). Such metabolic dysregulation could contribute to MMF function via disruption of cell signaling and membrane integrity. Another study shows that azathioprine reduced abnormally upregulated cellular cholesterol/lipid biosynthesis and uptake and induced ER stress and apoptosis in glioblastoma; this effect was likely mediated by blocking of EGFR/AKT/SREBP-1 signaling and not via the typical ABCA1-mediated cholesterol efflux through the LXR transcription factor, as neither LXR nor ABCA1 levels were altered by azathioprine (78). Interestingly, small-molecule inhibitors of sterol regulatory element–binding protein (SREBP) such as betulin, in addition to their antitumoral effects (79), can reduce cholesterol and fatty acid biosynthesis and atherogenic hyperlipidemia in animal models, suggesting that azathioprine could have a similar effect (80). SREBP-1 also reduces proinflammatory signaling and modulates macrophage phagocytosis (81, 82), additional pathways that could be affected by the inhibition of this transcription factor.

Methotrexate, sulfasalazine, and leflunomide. Methotrexate suppresses lymphocyte proliferation and cytokine production and increases apoptosis via multiple metabolic pathways (Table 2). Patients with RA have atypically reduced lipid levels considering their increased CVD risk (14); in line with this, recent studies show that methotrexate increases total cholesterol and LDL while reducing CVD risk (83), potentially by restoring normal lipoprotein metabolism (84, 85), although reduced proinflammatory cytokine levels and associated inflammation are also likely to play a role (86). The antiinflammatory mechanisms of sulfasalazine are also thought to have cardioprotective effects (87), potentially mediated by scavenging of oxygen radicals leading to decreased lipid peroxidation, inhibition of arachidonic acid metabolism via COX enzymes that results in reduced platelet aggregation, and inhibition of NF-κB signaling (88–91). Alternatively, sulfasalazine can induce ferroptosis, although it is not established whether this influences drug efficacy (ref. 36 and Figure 1F). Leflunomide, another antiproliferative drug, is known to increase hypertension and thus increase CVD risk, although the mechanism is unknown (ref. 92 and Table 2).

Cyclophosphamide. Cyclophosphamide can reduce LDL and VLDL levels and increase acetate (a lipid metabolism by-product) in lupus nephritis patients (93). However, acrolein, a cyclophosphamide metabolite (Table 1), can result in dose-related cardiotoxicity, which is a limiting factor for cyclophosphamide use (94). Acrolein alters levels of heart fatty acid–binding proteins, which deplete antioxidants and ATP levels through altered mitochondrial β-oxidation, thereby reducing the cellular energy pool. Together, these metabolic changes increase apoptosis in cardiomyocytes and can lead to heart failure and myocardial infarction (94). These off-target metabolic effects require close cyclophosphamide dose monitoring and modification in patients with AIRDs. There are few other reports that cyclophosphamide influences metabolite levels in AIRDs (95).

Target synthetic DMARDs

Target synthetic DMARDs (tsDMARDs) are small-molecule inhibitors used increasingly to treat AIRDs since they are less toxic, have fewer adverse effects, and have increased specificity to proteins and signaling pathways associated with disease pathogenesis (96). An array of tsDMARDs exist targeting key proinflammatory signaling pathways that are stimulated by inflammatory mediators (cytokines, chemokines, growth factors, and antigens), including JAK, MAPK, NF-κB, and spleen-associated tyrosine kinase (SYK)/Bruton’s tyrosine kinase (BTK) pathways (refs. 96–98 and Table 3). The full impact of inhibition of these pathways on specific metabolic mechanisms is unclear but likely plays an important role in the performance of specific tsDMARDs. Furthermore, crosstalk between various signaling pathways adds complexity to therapeutic strategies; for example, NF-κB target genes can inhibit MAPK signaling (99).

JAK inhibitors

JAK inhibitors block cell signaling via the JAK/STAT pathway (Table 3) but also have cell metabolic effects (including decreased mitochondrial membrane potential, mitochondrial mass, and ROS and inhibition of metabolic genes in synovial tissue) (100) and modify systemic lipid metabolism. Tofacitinib and baricitinib significantly increased HDL-C and LDL-C compared with baseline and other DMARD treatments alone in randomized controlled trials in RA and SLE (101–106), an effect reversed by statins (107). JAK inhibitors also improve HDL function by increasing the activity of lecithin–cholesterol acyltransferase (LCAT; an enzyme that converts free cholesterol to cholesterol esters and supports cholesterol efflux to lipoproteins), thereby increasing HDL efflux capacity (refs. 103, 106, and Figure 1C). Other effects such as alterations in lipoprotein size and content have been described (103, 108); therefore, these therapies may contribute to drug-induced dyslipidemia and exacerbate the lipid imbalances already associated
Table 2. Mechanisms of action of current conventional therapies used in AIRDs (part 2)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanisms/effects</th>
<th>Effects on lipid metabolism</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclophosphamide</td>
<td>Metabolized intracellularly into phosphoramide mustard, which induces apoptosis in T and B cells.</td>
<td>Mycophenolic acid (the active metabolite cyclophosphamide) activates PPARγ and increases intracellular lipids including fatty acids, cholesterol, and phosphatidylcholine in vitro.</td>
<td>75–77, 206–208</td>
</tr>
<tr>
<td></td>
<td>Lymphocytes rely solely on this pathway to generate guanine nucleotides; therefore, reduces DNA synthesis and subsequent proliferation and function in T cells and B cells.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Suppresses adhesion molecule expression and production of nitric oxide via iNOS by depleting guanosine 5′-triphosphate in lymphocytes/monocytes.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azathioprine</td>
<td>Inhibits leukocyte proliferation via inhibition of purine nucleotide synthesis.</td>
<td>Inhibits abnormally upregulated cellular cholesterol/lipid biosynthesis and uptake and induced ER stress and apoptosis in gliboblastoma via blocking EGFR/ Akt/SREBP-1 signaling.</td>
<td>75, 78, 209, 210</td>
</tr>
<tr>
<td></td>
<td>Reduces T cell proliferation and NFAT signaling and increases apoptosis.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metabolized into imidazole derivatives (with weak immunomodulatory effects) or 6-mercaptopurine, which is further metabolized into toxic nucleotides (e.g., 6-thioguanosine nucleotides), which inhibit amidotransferase enzymes and purine ribonucleotide interconversion and inhibit leukocyte proliferation.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Inhibits purine and pyrimidine synthesis, inhibits lymphocyte proliferation and cytokine production, and increases apoptosis.</td>
<td>Increases lipid oxidation indirectly through increased AMPK activation and blocking of PGE2 synthesis via inhibition of CDX-2. In RA, increases total cholesterol and LDL while reducing CVD risk, potentially by restoring normal lipoprotein metabolism, which is dysregulated in RA.</td>
<td>83–85, 211–219</td>
</tr>
<tr>
<td></td>
<td>Folate analog: metabolized into polyglutamates. Methotrexate polyglutamates bind with high affinity to dihydrofolate reductase and other enzymes that require folate cofactors such as AICAR transformylase and thymidylate synthetase, involved in purine and pyrimidine synthesis.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increases extracellular adenosine release. Adenosine has wide-ranging antiinflammatory effects: signaling via adenosine receptors on multiple cell types downregulates production of TNF, IL-6, and IL-18 and inhibits NF-κB signaling.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inhibits production of proinflammatory cytokines by blocking phosphorylation of JAK/STAT.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mediates increased apoptosis via increased ROS production; increases glucose uptake and lipid oxidation indirectly through AMPK activation by AICAR. Protects AIRD patients from metabolic syndrome by improving glucose metabolism.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>Metabolized by bacteria in the colon into its active metabolite 5-aminosalicylic acid, which acts through the lumen to confer its antiinflammatory effects through largely unknown mechanisms, which likely include interference with folate transporters and enzymes in the intestine, scavenging of oxygen radicals, PG inhibition via COX enzymes, and inhibition of NF-κB signaling.</td>
<td>Cardioprotective effects potentially mediated via scavenging of oxygen radicals leading to decreased lipid peroxidation; inhibition of arachidonic acid metabolism via COX enzymes, resulting in reduced platelet aggregation; and inhibition of NF-κB signaling. Can induce ferroptosis.</td>
<td>36, 87–91</td>
</tr>
<tr>
<td></td>
<td>Reduces T cell proliferation and IL-2 and IFN-γ production as well as monocyte IL-1 and TNF-α production and B cell and NK cell activity.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>In RA, increases total cholesterol and LDL while reducing CVD risk, potentially by restoring normal lipoprotein metabolism, which is dysregulated in RA.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increases lipid oxidation indirectly through increased AMPK activation and blocking of PGE2 synthesis via inhibition of CDX-2.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mediates increased apoptosis via increased ROS production; increases glucose uptake and lipid oxidation indirectly through AMPK activation by AICAR. Protects AIRD patients from metabolic syndrome by improving glucose metabolism.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inhibits production of proinflammatory cytokines by blocking phosphorylation of JAK/STAT.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leflunomide</td>
<td>Targets immune cell proliferation and activation by inhibiting pyrimidine synthesis.</td>
<td>Regulates abnormal expression of lipid rafts in B cells from SLE patients.</td>
<td>220, 221</td>
</tr>
<tr>
<td></td>
<td>Associated with increased risk of hypertension.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reduces LDL and VLDL levels and increases acetate (a lipid metabolism by-product) in lupus nephritis. Acronein induces dose-related cardiotoxicity: alters levels of heart fatty acid-binding proteins, which deplete antioxidants and AIP levels through altered mitochondrial respiration and decreases the cellular energy pool.</td>
<td></td>
<td>93, 94, 222–225</td>
</tr>
<tr>
<td></td>
<td>Phosphoramide mustard forms irreversible inter- and intra-strand DNA cross-links at guanine N7 positions, inducing cellular apoptosis due to inhibition of DNA replication required for proliferation.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Overview of the mechanisms of action of therapies used for patients with AIRDs and their effect on lipid metabolism pathways. AICAR, 5-aminimidazole-4-carboxamide ribonucleotide transformylase; AMPK, 5'-adenosine monophosphate–activated protein kinase; iNOS, inducible nitric oxide synthase; NFAT, nuclear factor of activated T cells; NF-κB, nuclear factor-κ-light-chain-enhancer of activated B cells; PG, prostaglandin; SREBP, sterol regulatory element–binding protein.

with AIRDs. Past trials have highlighted concerns surrounding the risk of arterial and venous thrombotic events with JAK inhibition, and emerging evidence suggests that this risk is dependent on JAK selectivity and is potentially confounded by indication (109, 110). Based on a review of a randomized controlled trial of tofacitinib versus anti-TNF treatment, the Food and Drug Administration issued an urgent revision for all JAK inhibitors to include information about potential increased risks of serious heart-related events, cancer, blood clots, and death. These emerging concerns are mirrored in recommendations to assess the benefits and risks for patients before initiating or continuing JAK inhibitor therapy (111).

Targeting the MAPK pathway

The MAPK pathway, comprising ERK, JNK, and p38 kinase (p38) (112), regulates cellular function via activation of transcription factors (Table 3). Although targeting of MAPKs such as p38 by VX-702 has shown clinical benefit in RA and animal models of SLE, the use of MAPK inhibitors is confounded by the vast and pleiotropic

Table 3. MAPK family members and their role in lipid metabolism

<table>
<thead>
<tr>
<th>MAPK</th>
<th>Function</th>
<th>Regulation</th>
<th>Therapeutic Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERK</td>
<td>Promotes cell survival and proliferation</td>
<td>Activated by growth factors</td>
<td>Inhibitors: U0126, PD98059, SB203580</td>
</tr>
<tr>
<td>JNK</td>
<td>Drives cell survival and apoptosis</td>
<td>Activated by stress and cytokines</td>
<td>Inhibitors: SP600125, JNK inhibitor II</td>
</tr>
<tr>
<td>p38</td>
<td>Induces cell survival and proinflammatory effect</td>
<td>Activated by stress and cytokines</td>
<td>Inhibitors: SB203580, JNK inhibitor II</td>
</tr>
</tbody>
</table>

REVIEW SERIES: IMMUNOMETABOLISM

References

7

J Clin Invest. 2022;132(2):e148552 https://doi.org/10.1172/JCI148552
effects of MAPKs on immune cell functions and cellular metabolism; this has resulted in multiple failures in clinical trials (96, 113). Mouse models of kinase deficiency clearly show that interconnected metabolic relationships exist between kinase function and liver-mediated lipid metabolism; altered activity and expression of MAPKs and their inactivating phosphatases are present in models of metabolic disease (114). Notably, downstream insulin signaling stimulates MAPK signaling, ERK can phosphorylate SREBP-2 (a regulator of cholesterol biosynthesis) (115), and ERK/JNK phosphorylates PPARY (116), linking the MAPK pathway to key regulators of lipid metabolism. The MAPK pathway can also be activated by JAK/STAT signaling (117).

Table 3. Mechanisms of action of tsDMARDs used in AIRDs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanisms/effects</th>
<th>Effects on lipid metabolism</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>JAK inhibitors</td>
<td>JAK inhibitors competitively bind to JAK ATP-binding sites and suppress JAK enzyme activity. JAKs are tyrosine kinases that bind to membrane receptors stimulated by inflammatory molecules such as interferon, which, upon activation, phosphorylate STAT transcription factors, which translocate to the nucleus and promote the expression of inflammatory genes. JAK inhibitors block signaling via numerous cytokine and hematopoietic growth factor receptors. Some SLE patients with a STAT4 risk allele responded better to JAK inhibitors. JAK/STAT signaling plays a fundamental role in metabolic homeostasis, including glucose tolerance and insulin sensitivity, in a cell-specific manner; e.g., stimulation of JAK/STAT3 signaling results in increased translocation of GLUT-4 to the plasma membrane in skeletal muscle cells, and JAK/STAT2 signaling can promote insulin resistance in myocytes. Approved for treatment of RA; clinical trials are ongoing for SLE.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increase HDL-C and LDL-C in RA and SLE patients. Improve HDL function and increase HDL efflux capacity by increasing the activity of LCAT (enzyme that converts free cholesterol to cholesterol esters and supports cholesterol efflux to lipoproteins). Could alter lipoprotein size and content.</td>
<td>101–106, 108, 226–231</td>
<td></td>
</tr>
<tr>
<td>MAPK inhibitors</td>
<td>MAPK inhibitors have pleiotropic effects on immune cell functions and cellular metabolism; this has resulted in multiple failures in clinical trials. The MAPK pathway is stimulated by growth factors, hormones, and inflammatory cytokines, and regulates many cellular functions, including cell cycle, apoptosis, and pro- or anti-inflammatory cytokine production such as TNF and IL-10 or IL-10. The MAPKs are split into 3 families: ERK, JNK, and p38 kinase. These regulate cellular function via activation of transcription factors. The MAPK pathway can also be activated by JAK/STAT signaling. Inhibition of p38 by VX-702 is beneficial in RA and animal models of SLE.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MAPK inhibitors could influence lipid metabolism: ERK phosphorylates SREBP-2 (a regulator of cholesterol biosynthesis), and ERK/JNK phosphorylates PPARY.</td>
<td>96, 112, 113, 115–117, 232–235</td>
<td></td>
</tr>
<tr>
<td>NF-κB inhibitors</td>
<td>Iglutimod is an inhibitor of RelA, a component of the NF-κB heterodimer, and is approved for use in patients with RA in China and Japan. Iglutimod reduces inflammatory responses such as T cell differentiation and antibody production by B cells but could also affect the cellular metabolic responses associated with NF-κB signaling. NF-κB is a heterodimer of transcription factors activated by canonical (cytokine receptors, pattern recognition receptors, and T cell and B cell receptors) and non-canonical pathways (ligands for the TNF receptor superfamily, receptor activator of NF-κB, CD40, and B cell–activating factor receptor). Inactivated NF-κB is complexed with the inhibitory protein IκBα in the cytosol; extracellular signals trigger the phosphorylation and dissociation of IκBα from NF-κB, allowing the translocation of activated NF-κB to the nucleus and transcription/promotion of proinflammatory cytokines, chemokines, adhesion molecules, and pathways controlling cell proliferation and differentiation.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reduce macrophage foam cell formation (lipid accumulation) via reduced expression of lipid transporters (ABCA1/ABCG1) and reduced cholesterol efflux, and increased lipid uptake via scavenger receptors. Antiinflammatory benefits via modulation of cell plasma membrane lipid rafts and reduction of TLR trafficking and signaling.</td>
<td>96, 119–125, 236–239</td>
<td></td>
</tr>
<tr>
<td>SYK/BTK inhibitors</td>
<td>Inhibition of SYK/BTK signaling pathways is a potential therapeutic target for RA and SLE owing to their role in B cell activation and proliferation. Multiple BTK inhibitors are currently in clinical trials for AIRDs. SYK and BTK are cytoplasmic nonreceptor tyrosine kinases; SYK/BTK activation leads to downstream signaling through MAPK-, NFAT-, and NF-κB–dependent pathways and has diverse implications including mobilization of intracellular calcium, cell proliferation, differentiation, and regulation of inflammatory gene expression. SYK-mediated signaling is proximal to multiple downstream signaling pathways, including the MAPK and NF-κB pathways. T cells express low levels of SYK and BTK, but increased SYK is found in T cells from SLE patients. SYK is elevated in B cells from patients with RA.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BTK inhibition can inhibit free fatty acid metabolism in chronic lymphocytic leukemia through a reduction of lipoprotein lipase.</td>
<td>96, 128, 129, 240–244</td>
<td></td>
</tr>
</tbody>
</table>
Targeting NF-κB signaling
Aberrant NF-κB signaling is implicated in many inflammatory (RA, SLE) and metabolic (atherosclerosis, obesity, diabetes) diseases (118, 119). Ixugaramod, an inhibitor of RelA, a component of the NF-κB heterodimer, is approved for use in patients with RA in China and Japan (refs. 120, 121, and Table 3). Ixugaramod could also affect the cellular metabolic responses associated with NF-κB signaling, including macrophage foam cell formation (lipid accumulation), via reduced expression of lipid transporters (ABCA1 and ABCG1), reduced cholesterol efflux, and increased lipid uptake via scavenger receptors (refs. 122, 123, and Figure 1C). Blocking NF-κB signaling could therefore increase cellular cholesterol efflux and reduce lipid uptake, with both atheroprotective implications through reduced foam cell formation (124) and antiinflammatory benefits via modulation of cell plasma membrane lipid rafts and reduction of Toll-like receptor trafficking and signaling (125). Alternatively, inhibition of NF-κB activation in macrophages can increase atherosclerosis in LDLR-deficient mice (126); disparity between studies may be due to different models and experimental approaches, indicating that such off-target effects need to be studied in more detail in patients. Additionally, the atheroprotection transcription factor PPARα, activated by endogenous fatty acid ligands such as arachidonic acid, can suppress entry of NF-κB to the nucleus owing to increased IκBa expression (127), demonstrating the complexity of NF-κB signaling in lipid metabolism.

Targeting SYK/BTK pathways
Finally, SYK/BTK-mediated signaling is proximal to multiple downstream signaling pathways, including the MAPK and NF-κB pathways (ref. 128 and Table 3); BTK inhibition can inhibit free fatty acid metabolism in chronic lymphocytic leukemia through reduction of lipoprotein lipase (129). Furthermore, crosstalk between BTK signaling and bioenergetic stress responses in leukemic B cells suggests that cellular metabolic rewiring could mediate the metabolic effects of these molecules (130). Multiple BTK inhibitors are currently in clinical trials for AIRDs.

Biologics
Biologic therapies are target specific and, despite their eventual catabolism by proteases and complications surrounding anti-drug antibodies, they do not undergo in vivo metabolism within immune cells to elicit their desired effects (ref. 131 and Table 4). Notably, several biologics influence lipid and lipoprotein metabolism, and it is likely that biologics have additional indirect metabolic actions associated with preventing inflammatory cytokines from binding their receptors, as seen with JAK inhibitors (132, 133).

IL-6 receptor antagonists
Tocilizumab and sarilumab inhibit IL-6 receptor binding to IL-6 and block downstream signaling via multiple pathways, including JAK/STAT, p38/JNK, and MAPK (134). Patients with RA are typically characterized by low levels of LDL, potentially due to LDL-C hypercatabolism driven by the IL-6/acute-phase response (85). By blocking hepatic IL-6 signaling, tocilizumab restores LDL-C metabolism and increases serum LDL-C (85, 135, 136). Tocilizumab also increases HDL and triglyceride serum levels in RA patients (137) and promotes HDL cellular cholesterol efflux capacity (ref. 138 and Figure 1C).

TNF inhibitors
Treatment with TNF inhibitors (e.g., etanercept or adalimumab) also increases HDL, total cholesterol, and triglycerides, while the apolipoprotein B/apolipoprotein A1 ratio is decreased and LDL-C levels remain unchanged (139). These effects could reduce CVD risk in RA patients (140), potentially by altering the HDL-associated proteome and improving HDL function, when inflammation is reduced by either adalimumab or abatacept (CTLA-4 fusion protein blocking CD80/CD86 costimulation) (141). Interestingly, adalimumab was associated with higher HDL-associated serum amyloid A-I in comparison with patients treated with abatacept (141). It has also been shown that RA patients receiving tocilizumab have a greater increase in LDL-C levels compared with those treated with adalimumab (142), highlighting the differential effects of various biologics on lipid metabolism.

Rituximab
Several studies have reported altered lipid profiles following rituximab (anti-CD20 monoclonal antibody) treatment in AIRDs. In SLE, rituximab reduced triglycerides and resultant atherogenic index of plasma values, likely associated with improvement in disease activity, although reductions in total cholesterol and LDL-C did not reach statistical significance and HDL levels remained stable (143). In contrast, a separate study showed that RA patients treated with rituximab had reduced total cholesterol and HDL levels associated with improved endothelial function and decreased carotid intima-media thickness (144), supporting beneficial metabolic effects. However, another study investigating RA patients responding to rituximab therapy only partially replicated this, showing an increase in total cholesterol and HDL with a paradoxical decreased atherogenic index of plasma and carotid intima-media thickness (145). The disparities between these studies could be dependent on the level of baseline dyslipidemia.

It is plausible that biologic therapies influence systemic lipid metabolism partly via the general dampening of inflammation, particularly considering that the liver is largely responsible for circulating lipoprotein metabolism, as seen in transplant recipients (146). This could also be due to altered hepatic cytokine signaling, as, for example, TNF-α can reduce lipoprotein lipase activity and liver metabolism (147), while in hepatic steatosis IL-1 signaling increased fatty acid synthase expression and triglyceride accumulation (148). Alternatively, in RA, blocking hepatic IL-6 signaling (tocilizumab) restored normal LDL catabolism induced by IL-6 suppression of CYP enzymes. Normalizing CYP enzyme expression could also have a wider effect on cell metabolism generally (85). The effect of anti–IL-17 antibodies (secukinumab) on lipid metabolism remains uncertain, with reports showing increased, unchanged, or reduced HDL and cholesterol levels as well as increased triglyceride levels (149). This uncertainty exists even though IL-17, a proinflammatory cytokine implicated in AIRD and atherosclerosis pathogenesis, is known to affect cholesterol and lipoprotein metabolism (150, 151) and promote foamy macrophage formation (152).

Immune cell lipid metabolism could also be influenced by biologics. Recently, IFNs were shown to have differential effects on membrane cholesterol metabolism in macrophages, including downregulation of cholesterol biosynthesis (153, 154); this effect was not observed with TNF-α, IL-1β, or IL-6, suggesting that new
Reduced cholesterol esterification in CD8+ T cells increased plasma py shows that inhibition of acetyl-CoA acetyltransferase-1 (ACAT1), an effect that was also inhibited by cholesterol depletion (155). However, binding of anti-CD20 antibodies can also trigger antiapoptotic signaling via SYK and AKT pathway; e.g., IL-1 and TNF-α stimulate MAPK signaling and cross-activate NF-κB and are blocked by direct TNFIs and IL-2 receptor antagonists. Biologics have additional indirect metabolic actions associated with preventing inflammatory cytokines from binding their receptors as with JAK inhibitors.

### Table 4. Mechanisms of action of biologic therapies used in AIRDs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanisms/effects</th>
<th>Effects on lipid metabolism</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biologics</td>
<td>Target specific therapies that do not undergo in vivo metabolism and include monoclonal antibodies or fusion proteins against specific immunoregulatory proteins such as proinflammatory cytokines and their receptors — e.g., TNFIs; IL-1 receptor; anti–IL-6 receptor and anti-type I IFN receptor antagonists, anti–IL-12/23, and anti–IL-17; and immune cell receptors (anti-CD20, anti-CD40L, anti-B cell–activating factor, and CTLA-4 fusion protein blocking CD80 and CD86). Block signaling pathways targeted by tsDMARDs including MAPK, NF-κB, and JAK/STAT pathways; e.g., IL-1 and TNF-α stimulate MAPK signaling and cross-activate NF-κB and are blocked by direct TNFIs and IL-2 receptor antagonists.</td>
<td>IL-6 receptor agonists restore LDL-C metabolism and increase serum LDI, increase HDL and triglyceride serum levels in RA patients, and promote HDL cellular cholesterol efflux capacity. TNFIs increase HDL, total cholesterol, and triglycerides and decrease apolipoprotein B/apolipoprotein A1. They potentially alter the HDL-associated proteome and improve HDL function — higher HDL-associated serotransferrin and immunoglobulin J chain and lower serum amyloid A-1. In SLE, rituximab reduces triglycerides and had a trend toward lowered total cholesterol and LDL. In RA, rituximab reduces total cholesterol and HDL levels, improves endothelial function, and decreases carotid intima-media thickness. Another study showed increased total cholesterol and HDL and decreased carotid intima-media thickness. Modulation of lipid rafts, potentially by alteration in lipoprotein-mediated cholesterol uptake or efflux, could influence rituximab efficacy. Anti–IL-17 antibodies show increased, unchanged, or reduced HDL and cholesterol levels and increased triglycerides levels.</td>
<td>85, 131–133, 135–139, 141, 143, 144, 149, 155, 245–248</td>
</tr>
</tbody>
</table>

Overview of the mechanisms of action of therapies used for patients with AIRDs and their effect on lipid metabolism pathways. NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; TNFIs, TNF inhibitors.

Therapies such as anifrolumab (anti-type I IFN receptor antibody) could have effects on both systemic (hepatic) and local (immune cell) lipid metabolism. Changes in immune cell lipid metabolism can also influence cell signaling via changes in lipid rafts (9, 68). By binding membrane CD20, rituximab induces its translocation to lipid rafts, which is crucial, under some conditions, for induction of B cell apoptosis and can be prevented by disruption of lipid rafts by cholesterol depletion (155). However, binding of anti-CD20 antibodies can also trigger antiapoptotic signaling via SYK and AKT pathways, an effect that was also inhibited by cholesterol depletion (156, 157). Thus, modulation of lipid rafts, potentially by alteration of lipoprotein-mediated cholesterol uptake or efflux, could influence drug efficacy. Experimental evidence in cancer immunotherapy shows that inhibition of acetyl-CoA acetyltransferase-1 (ACAT1), an enzyme that increases intracellular esterified cholesterol levels, improves the efficacy of anti–PD-1 therapy in melanoma (158). Reduced cholesterol esterification in CD8+ T cells increased plasma membrane cholesterol levels and subsequent lipid raft–associated T cell receptor clustering and signaling, thereby increasing T cell cytotoxicity against melanoma growth. ACAT inhibition can also boost the antiviral activity of CD8+ T cells against hepatitis B by promoting lipid raft signaling in vitro (159).

### Advances supporting metabolism- and inflammation-targeted therapies in AIRDs

Chronic inflammation and dyslipidemia (which can be exacerbated by current therapies) both contribute to increased CVD risk in patients with AIRDs. However, studies show that lipid-lowering drugs (such as statins) are not sufficient to reduce CVD risk in some AIRDs, possibly because they cannot completely restore the antiinflammatory properties of HDL (160, 161). Thus, an unmet clinical need exists for better therapies to address both inflammation and atherosclerosis.

Altered lipid metabolism is frequently associated with the use of nonselective and targeted AIRD treatments. The impact of therapy on lipid profiles can be beneficial, as in the case of hydroxychloroquine, which reduces LDL-C in SLE (63), or lead to new drug-induced dyslipidemia or exacerbate current dyslipidemia associated with AIRD (Tables 1–4) with various clinical outcomes. In the context of high mortality rates associated with CVD in AIRDs, lipid modification therapies are a key cotherapy of interest. Statins are inhibitors of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, that reduce levels of circulating cholesterol, particularly cholesterol carried in LDL particles. Atorvastatin can reverse tofacinib-induced elevation of total cholesterol, LDL-C, and triglycerides in patients with RA (107), and patients treated with statins for over 6 months have improved disease activity scores in comparison with conventional RA therapies, supporting a potential beneficial role for statins in patients with active RA (162). Other trials have assessed the use of statins to reduce inflammation. High-dose statins reduced brain atrophy and disability progression in patients with secondary progressive multiple sclerosis in a randomized controlled trial (163, 164). Statins have also been tested in SLE to treat inflammation and dyslipidemia, with mixed outcomes. Some studies show beneficial effects such as improved lipid and inflammatory cytokine levels and reductions in vascular inflammation, atherosclerotic plaque progression, mortality, and morbidity (165–168). However, statins have not met their primary endpoint in clinical trials, including the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial.
in children (169) and the Lupus Atherosclerosis Prevention Study (LAPS) in adults (170). Interestingly, although the LAPS 2-year intervention trial did not meet the atherosclerosis primary and secondary endpoints, significant changes in lipid profiles [lipoprotein(a) and total cholesterol] were reported. Difficulties in stratifying patients based on their initial dyslipidemia status as well as their background medication could be the reason for this.

Recent studies of lipoprotein taxonomy in patients with adult and juvenile-onset SLE (171, 172) and multiple sclerosis (173) have highlighted the heterogeneity in patient lipoprotein profiles. Therefore, baseline lipid levels could be important predictors of therapeutic benefit, as has been shown in RA patients treated with tocilizumab and JAK inhibitors, among whom patients with increased lipid levels had a better response to lipid-lowering drugs (107, 135). Other therapies targeting lipid metabolism include reconstituted HDL (shown to reduce plaque in lipid content, macrophage size, and inflammation; ref. 174) and the recently approved statin alternative inclisiran, which increases LDLR levels in the liver (by inhibiting proprotein convertase subtilisin/kexin type 9, the enzyme responsible for LDLR inhibition), thereby reducing LDL-C in the blood by up to 50%, similarly to high-dose statins (175). In the future, new lipid-modifying drugs could be used as an alternative to, or in combination with, statins for patients with AIRDs and dyslipidemia not controlled by conventional treatment and at high risk of cardiovascular events, particularly in those on antinflammatory treatments that exacerbate dyslipidemia as discussed above.

Some immune receptors that reside in lipid rafts are targeted by AIRD treatments—including CD20 targeted by rituximab (155), CD80/CD86 targeted by abatacept (141), and IL-6R targeted by tocilizumab (176)—suggesting that lipid modification could potentially alter the efficiency of these therapies by regulating membrane turnover of these receptor targets. Some biologic agents require intact lipid rafts to exert their therapeutic function, e.g., rituximab (155–157). Furthermore, pharmacologic inhibition of lipid raft components (cholesterol and glycosphingolipids) using statins and glycolipid synthase inhibitors (N-butyldexoxynojirimycin) restored defective lipid raft levels and normalized in vitro function in CD4+ T cells from patients with SLE. This included T cell receptor signaling and function and anti-dsDNA antibody production by autologous B cells (10, 177). Interestingly, elevated glycosphingolipid levels in SLE T cells were associated with the increased expression of the LXR master lipid transcriptional regulator, which directly modulates enzymes involved in glycosphingolipid synthesis (9). Whether supplementation with compounds targeting LXR could further modulate lipid rafts and AIRD drug efficacies remains to be explored.

In some circumstances, the dose of lipid-modifying therapies must be adjusted when they are used in combination with AIRD therapies. Tocilizumab normalizes CYP enzyme expression and increases LDL-C; therefore patients on statin cotherapy may require an increased dose to maintain therapeutic lipid-lowering benefits (135). Cyclosporin can also affect the pharmacokinetics of statins through the inhibition of both organic anion transporter polypeptide-1B1 and CYP3A4 (178). Also, lipids including HDL play an important role as SIP chaperones; therefore, alterations in lipoprotein metabolism could influence the efficacy of drugs modulating the SIP pathway (e.g., fingolimod), which are now used in multiple sclerosis and being investigated in AIRDs (34, 179).

Dietary patterns also modify inflammation; those with a higher inflammatory potential are significantly associated with unfavorable lipid profiles and a higher incidence of CVD (180). Despite these observations, the relationship between nutrition and inflammation in AIRDs is not well established. Oral lipid supplements may aid the effectiveness of conventional therapies, such as essential fatty acid supplementation to increase STM levels; these have been linked to decreased joint pain and predict DMARD responsiveness in RA (31). Dietary polyunsaturated fatty acids can also inhibit ferrisopptosis (181) and incorporate into T cell membranes, thus altering plasma membrane phospholipid expression and the localization of immunogenic receptors such as IL-2 receptor and Fc receptors into lipid raft microdomains (182). Dietary intervention to alter blood lipids can be beneficial in SLE and RA and reduce disease activity scores (183–185). Increased dietary intake of omega-3 fatty acids increased HDL and reduced triglycerides in juvenile-onset SLE (183, 186) and increased HDL and reduced VLDL in adult SLE (187). Thus omega-3 dietary supplements could be promising therapeutic options for some patients. In contrast, a randomized controlled trial of dietary restrictive patterns reduced weight and fatigue in adults with SLE, but did not affect disease activity or cardiovascular parameters including lipid profiles and inflammatory markers (188).

Conclusion

Understanding how lipid metabolism influences immune responses and the effect of both conventional and new therapies on lipid metabolism is an ongoing challenge but could identify new ways to target AIRDs. Better control of inflammation using optimal combinations of immunosuppressive treatments, as shown in inflammatory bowel disease (189), could lead to an improved metabolic/lipid profile in AIRDs. Improved monitoring of pro-/antiinflammatory lipoprotein fractions using a granular lipoprotein taxonomy approach and improved CVD risk stratification biomarkers (171, 172), rather than total HDL/LDL levels, could improve targeted patient management. This is relevant since statins do not completely normalize proinflammatory HDL fractions (160). Such improved monitoring could enable novel combination interventions, such as nonspecific dietary intervention with specific lipid lowering and targeted antiinflammatory therapy. Finally, the clinical relevance of metabolic/lipid biomarkers in AIRDs needs to be explored in long-term studies to capture the long-term toxicity of combined therapies as well as their impact on cardiovascular events.

Acknowledgments

GAR is supported by Lupus UK, the Rosetrees Trust (M409), and a National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre grant (BRC773/III/CC/101350). IPT is funded by a Medical Research Council New Investigator Grant (G0801278), a British Heart Foundation Project Grant (PG/13/10/30000), and an Academy of Medical Sciences Newton Advanced Fellowship. CC is supported by a grant from the Centre for Adolescent Rheumatology Versus Arthritis at University College London UCLH and Great Ormond Street Hospital (GOSH) supported by grants from Versus Arthritis (21593 and 20164), Great Ormond Street Hospital Children’s Charity (GOSCC), and the NIHR Biomedical Research Centres at both GOSH and UCLH. ECJ is supported by grants from the Dunhill Medical Trust.
REVIEW SERIES: IMMUNOMETABOLISM

The Journal of Clinical Investigation

(RPGF1902;117) and NIHR UCLH Biomedical Research Centre grant BRC772/III/E/1/101350 and Fast Track grant F215. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.

Address correspondence to: Elizabeth C. Jury, Centre for Rheumatology Research, University College London, 4th Floor Rayne Institute, 5 University Street, London WC1E 6JF, United Kingdom. Phone: 44.0.20.3108.2161; Email: e.jury@ucl.ac.uk.


REVIEW SERIES: IMMUNOMETABOLISM


147. Glennie MJ, et al. Mechanisms of killing by anti-


